Abstract:Glioblastoma is the most frequent and malignant primary brain tumor. Although the survival is generally dismal for glioblastoma patients, risk stratification and the identification of high-risk subgroups is important for prompt and aggressive management. The G1-G7 molecular subgroup classification based on the MAPK pathway activation has offered for the first time a non-redundant, all-inclusive classification of adult glioblastoma. Five patients from the large, 220-patient prospective cohort showed germline mutations in mismatch repair (MMR) genes and significantly worse median survival (3.25 months post-surgery) than those from other subgroups or from the rest of the cohort adjusted for age. These tumors were assigned to a new subgroup, G3/MMR, a spin-off from the major G3/NF1 subgroup, as they generally show genomic alterations leading to RAS activation. An integrated clinical, histological, immunohistochemical and molecular analysis of the G3/MMR tumors showed distinct characteristics as compared to other glioblastomas, including those with iatrogenic high tumor mutation burden (TMB), warranting a separate subgroup. Among these, prior history of cancer, midline location or multifocality, presence of multinucleated giant cells, positive p53 and MMR immunohistochemistry, and specific molecular characteristics, including high TMB, alert to this high-risk G3/MMR subgroup. High TMB constitutes the criterium for treatment with immune checkpoint inhibitors in solid cancers. The FDA-approved first-line therapy for advanced non-small cell lung cancer and high-TMB colorectal cancer is with the dual ipilimumab-nivolumab regimen. One of the five G3/MMR subgroup patients received the dual ipilimumab-nivolumab regimen and survived much longer than the rest of the G3/MMR patients, setting a proof-of-principle example for the treatment of these very aggressive G3/MMR glioblastomas.

Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma

PATH-08. EVALUATION OF MISMATCH REPAIR GENE EXPRESSION BY IMMUNOHISTOCHEMISTRY MAY DETECT EARLY PHASE OF MMR DEFICIENCY IN RECURRENT GLIOMAS

Mechanisms and therapeutic implications of hypermutation in gliomas

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition

Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma

Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome

Comparison of Glioblastoma (GBM) Molecular Classification Methods

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment

Innv-06. Adult Glioblastoma With Mismatch Repair Deficiency Forms A Distinct High-Risk Molecular Subgroup For Which Treatment With Ipilimumab-Nivolumab Shows Survival Advantage

Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?

Identification of a novel glioblastoma multiforme molecular subtype with poor prognosis and high immune infiltration based on oxidative stress-related genes

Diagnostic and therapeutic challenges of glioblastoma as an initial malignancy of constitutional mismatch repair deficiency (CMMRD): two case reports and a literature review

Molecular Characterization and Survival Analysis of a Cohort of Glioblastoma, IDH-wildtype

Comprehensive somatic mutational analysis in glioblastoma: Implications for precision medicine approaches

A Genome-Wide Allelotype Study of Primary and Corresponding Recurrent Glioblastoma Multiforme in One Patient

Whole‐exome Sequencing Revealed Mutational Profiles of Giant Cell Glioblastomas

DNAR-09. THE ROLE OF MSH2 IN GLIOBLASTOMA GROWTH AND TEMOZOLOMIDE RESISTANCE

Association of MSH6 mutation with glioma susceptibility, drug resistance and progression.